ClinicalTrials.gg
RecruitingNCT06482138DysOSMICUpdated May 6, 2026

Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation

An interventional study of Biopsy and Cytobrush in Covid19 and Olfactory Dysfunction, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in COVID-19 with a site in Belgium — 11 open to participants now, 16 under way, 6 of them phase 3. COVID-19 · Belgium.

Planned enrollment
37th of 103
240 · median 150
Started
2024
with 3 others
No phase
38 of 173
2 open now
Primary completion
2026-12
later than 6 of 15 live
Registered
168th of 173
by date
Lead sponsor
8 of 173
Universitaire Ziekenhuizen KU Leuven

Among the 173 studies in COVID-19 with a site in Belgium, this one is the 37th largest by planned enrollment of the 103 interventional ones that give a count, is one of 4 that started in 2024, is one of 38 with no phase, reaches primary completion later than 6 of the 15 other live ones, and was the 168th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

11 of the 173 studies in COVID-19 with a site in Belgium are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in COVID-19 with a site in Belgium, or all of them as a file.
02

Study summary

Investigation of the mechanisms of persistent SARS-CoV-2 associated olfactory dysfunction (OD) in patients with well-documented olfactory function. The investigators plan to collect olfactory cleft biopsies and cytobrushes in COVID-19 patients and controls.

Read the detailed description

An explorative prospective clinical study using human body materials of living post-COVID-19 patients with and without OD, to study the mechanisms of persisting olfactory dysfunction. Patients consult ENT specialist for medical purposes and undergo standard-of-care diagnostics and management. The collected tissues from the olfactory cleft mucosa will be analyzed using single cell RNA sequencing and RNAscope combined with immunohistochemistry.

03

Conditions studied

  • Covid19
  • Olfactory Dysfunction

Browse trials for

Keywords

  • Olfactory Dysfunction
  • COVID-19
  • SARS-CoV-2
  • Anosmia
  • Hyposmia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Olfactory Dysfunction group: Presence of evident OD (Parosmia, Threshold-Discrimination-Identification (TDI)-score ≤24, Subjective abnormal quantitative olfactory function; measured by a visual analogue score (VAS) of smell impairment ≥5/10
  • Control group: No OD (TDI-score >30.5.)

Exclusion criteria

Exclusion Criteria:

  • Presence of concomitant nasal mucosal pathology that might affect olfactory function or bias the study investigations
  • Use of anticoagulation therapy
  • Allergy to local anesthetics
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Other
    Control

    Biopsy and cytobrush during a scheduled structural intervention in general anesthesia

    Procedure: Biopsy and Cytobrush

  • Other
    Olfactory Dysfunction

    Biopsy and cytobrush during consultation in local anesthesia

    Procedure: Biopsy and Cytobrush

Interventions

  • ProcedureBiopsy and Cytobrush

    Collection of olfactory cleft biopsies and cytobrushes

06

What researchers measure

Primary outcomes

  1. Analysis of olfactory cleft biopsies

    Morphological and histomolecular differences between OD and control patients * Evaluating tissue pathology: * Metaplasia * hypertrophy * aberrant scar formation * apoptosis * presence of inflammatory cells \[H\&E, CD68 and CD3 stainings, RNAscope\] * Presence of SARS-CoV-2 RNA * Percentage of OSNs versus sustentacular cells; maturation of OSNs

    Time frame: From enrollment of 1 patient until analyzed, 1 month

  2. Analysis of olfactory cytobrushes

    Morphological and histomolecular differences between OD and control patients * Evaluating tissue pathology: * Metaplasia * hypertrophy * aberrant scar formation * apoptosis * presence of inflammatory cells \[H\&E, CD68 and CD3 stainings, RNAscope\] * Presence of SARS-CoV-2 RNA * In the olfactory epithelium: percentage of OSNs versus sustentacular cells; maturation of OSNs

    Time frame: From enrollment of 1 patient until analyzed, 1 month

07

Study locations

6 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 35 months is above that.

Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Jul 1, 2024
StartActual
Jan 24, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06482138
Collaborators
University Hospital, Geneva, Max Planck Research Unit for Neurogenetics, University Hospital Carl Gustav Carus, University of Zurich
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Jan 24, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 6, 2026

Study contacts

Laura van Gerven
Contact
laura.vangerven@uzleuven.be
+3216336342
Sabrina Bischoff
Contact
sabrina.bischoff@uzleuven.be
+41763655671
Laura van Gerven
principal investigator · UZ/KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion